Navigation Links
KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva(TM)
Date:1/22/2008

continue to expand its focus on women and their babies as a complement to Ther-Rx's leading selling line of branded prenatal vitamins.

About KV Pharmaceutical Company

KV Pharmaceutical Company is a fully integrated specialty pharmaceutical company that develops, manufactures, markets and acquires technology-distinguished branded and generic/non-branded prescription pharmaceutical products. The Company markets its technology-distinguished products through ETHEX Corporation, a national leader in pharmaceuticals that compete with branded products, and Ther-Rx Corporation, its branded prescription pharmaceutical subsidiary.

For further information about KV Pharmaceutical Company, please visit the Company's corporate website at http://www.kvpharmaceutical.com.

Safe Harbor

The information in this release may contain various forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 ("PSLRA") and which may be based on or include assumptions concerning KV's operations, future results and prospects. Such statements may be identified by the use of words like "plans," "expect," "aim," "believe," "projects," "anticipates," "commit," "intend," "estimate," "will," "should," "could" and other expressions that indicate future events and trends.

All statements that address expectations or projections about the future, including without limitation, statements about the Company's strategy for growth, product development, product launches, regulatory approvals, market position, market share increases, acquisitions, revenues, expenditures and other financial results, are forward-looking statements.

All forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the "safe harbor" provisions, KV provides the following cautionary statements identifying important e
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Wyeth and Teva Pharmaceuticals Extend the Standstill Period Relating to Tevas Launch of Generic Pantoprazole
2. Pharmaceutical market fails pregnant women; and more
3. Bradley Pharmaceuticals Announces Filing of Definitive Proxy Statement for Special Meeting of Stockholders to Approve Merger With Nycomed
4. MAP Pharmaceuticals Reaches Agreement with FDA on Special Protocol Assessment for MAP0004 Phase 3 Clinical Trial in Patients With Migraine
5. Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Metaglip(R)
7. Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Childrens Zyrtec(R) Chewable Tablets for Allergy Relief and Childrens Zyrtec(R) Chewable Tablets for Hives Relief
9. Global Pharmaceutical Launches: Best Practices for Winning Product Launch Successes
10. Breckenridge Pharmaceutical Settles Paragraph IV Litigation and Receives FDA Approval for its Oxcarbazepine ANDA
11. Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... Aliso Viejo, California (PRWEB) August 31, 2014 ... release of ProPixie 5K. This plugin is a composite footage ... Cut Pro X. , “Adding particle footage to a video ... Christina Austin, CEO of Pixel Film Studios. “ProPixie 5K gives ... Editors can give their film an epic or magical ...
(Date:8/31/2014)... (PRWEB) August 31, 2014 With the ... Conflict Institute hosted an interview with Yale University ... as well as Yale’s approach to ensuring student-athlete experience ... the interview, Conn highlighted a number of key factors ... university. A critical factor in creating this culture ...
(Date:8/31/2014)... 31 August 2014: Mortality and morbidity of atrial ... good use of oral anticoagulants, according to the one ... Registry. The findings were presented for the first time ... Gregory Lip (Birmingham, UK). , Professor Lip said: "This ... management practices of European cardiologists conducted since the ESC ...
(Date:8/30/2014)... Florida (PRWEB) August 31, 2014 Walking-Canes.Net ... walking and how a mobility device can help in making ... available for free download from the website that contains all ... doctor for this site. , The articles deal with diseases ... device like a walking cane can help in making life ...
(Date:8/30/2014)... August 31, 2014 This Labor Day, ... growing union in New York State and nationwide, is ... jobs and the best quality of care to New ... recent years, thousands of healthcare workers in the region ... families by becoming members of the healthcare workers’ union. ...
Breaking Medicine News(10 mins):Health News:Announcing a New ProPixie 5K Composite Footage Pack from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:Yale University’s Steve Conn Discusses NCAA Football, Student-Athlete Experience, & Social Media SCI Talk Interview 2Health News:Yale University’s Steve Conn Discusses NCAA Football, Student-Athlete Experience, & Social Media SCI Talk Interview 3Health News:AF mortality and morbidity high at 1 year despite good anticoagulant use 2Health News:Information Articles on Gait Problems from Walking-Canes.Net 2Health News:This Labor Day, 1199SEIU Continues Commitment to Growing Local Economies with Good, Middle-Class Healthcare Jobs 2Health News:This Labor Day, 1199SEIU Continues Commitment to Growing Local Economies with Good, Middle-Class Healthcare Jobs 3Health News:This Labor Day, 1199SEIU Continues Commitment to Growing Local Economies with Good, Middle-Class Healthcare Jobs 4
... ... ... , ... , , ...
... ... use of mobile technology and their participation in online physician networking. Approximately 30% ... popular handheld device or smartphone is the Apple iPhone, with 31% of respondents owning ... Plymouth ...
... trouble by mid-40s, despite activity levels, study finds , WEDNESDAY, March ... 20s and 30s are more apt to develop heart disease risk ... spent less time in front of the screen, a new study ... news is that you can,t exercise the risk away. , The ...
... ... ... , , , ... ...
... ... ... ... ...
... , ... ... ... ...
Cached Medicine News:Health News:Statement from Larry Minnix, President & CEO, American Association of Homes and Services for the Aging, On the Therapy Cap Coalition Press Conference 2Health News:SDI Reports: Nearly a Third Of Physicians Use Handheld and Smartphone Devices to Access Medical Information - Physicians Most Likely to be Using Apple iPhone 2Health News:SDI Reports: Nearly a Third Of Physicians Use Handheld and Smartphone Devices to Access Medical Information - Physicians Most Likely to be Using Apple iPhone 3Health News:You Can't Exercise Away TV's Toll on the Heart 2Health News:You Can't Exercise Away TV's Toll on the Heart 3Health News:March of Dimes President Dr. Jennifer L. Howse Wins Prestigious Humanitarian Award 2Health News:March of Dimes President Dr. Jennifer L. Howse Wins Prestigious Humanitarian Award 3Health News:March of Dimes President Dr. Jennifer L. Howse Wins Prestigious Humanitarian Award 4Health News:Kaiser Permanente Completes Electronic Health Record Implementation 2Health News:Kaiser Permanente Completes Electronic Health Record Implementation 3Health News:Kaiser Permanente Completes Electronic Health Record Implementation 4Health News:Kaiser Permanente Completes Electronic Health Record Implementation 5Health News:Kaiser Permanente Completes Electronic Health Record Implementation 6Health News:Seattle Sutton's Healthy Eating Sponsoring The Biggest Loser Chicago Casting Call 2Health News:Seattle Sutton's Healthy Eating Sponsoring The Biggest Loser Chicago Casting Call 3Health News:Seattle Sutton's Healthy Eating Sponsoring The Biggest Loser Chicago Casting Call 4
(Date:8/29/2014)... , Aug. 29, 2014 Medina Medical announced ... and member of the Board of Directors on August ... device development and commercialization experience, including over a decade ... previously served as a Partner of the medical device ... CEO of two Foundry start-ups. Mr. Engelson previously served ...
(Date:8/29/2014)... Research and Markets  has announced the addition of the ... to their offering. The Central Nervous System ... segments of pharmaceuticals industry. The numbers of CNS disorders have ... unable to meet the market requirements. There has been steady ... over the past two decades. The market for CNS therapies ...
(Date:8/29/2014)... Corporation , a neurodiagnostics medical device company based in ... Forcht Dagi , MD, DmedSc, MPH, MBA, FACS, FRCSEd  was ... " Teo Forcht Dagi is an experienced leader with ... said Remis Bistras , President and CEO of Vittamed. ... entrepreneurial expertise to our Board." Dr. Dagi is ...
Breaking Medicine Technology:Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2US CNS Disorders Drug Pipeline Insight 2014 2Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2
... Data Reviewed in End of Phase 2a Meeting , ... (Nasdaq: VIAP ), a biotechnology company focused on ... metabolic disease, announced today that an end of Phase 2a ... held with the U.S. Food and Drug Administration (FDA). ...
... New Capabilities Will Further Extend GeneXpert System Technology Advantages , ... CPHD ) today announced that it has received a ... and Infectious Diseases to develop new ten-color detection technology for ... be awarded to Cepheid and the University of Medicine ...
Cached Medicine Technology:VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 2VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 3VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 5Cepheid Receives Grant to Develop Ten-Color Real-Time PCR Detection Technology for Use in the GeneXpert(R) System 2Cepheid Receives Grant to Develop Ten-Color Real-Time PCR Detection Technology for Use in the GeneXpert(R) System 3Cepheid Receives Grant to Develop Ten-Color Real-Time PCR Detection Technology for Use in the GeneXpert(R) System 4
This compression garment can be used following Abdominoplasty, Tram Flap, Abdominal Liposuction, Lipoplasty, Suction,Lipectomy, Stomach Liposuction, Liposculpture, TummyTuck....
Select Support Brief...
Female High Waist Briefs...
Arm Compression Garment...
Medicine Products: